Glyciphage-PG 1 Tablet
Glyciphage-PG 1 Tablet Sr is used for the management of non-insulin-dependent diabetes mellitus (type 2) as an adjunct to diet and exercise to lower blood glucose. Used in combination with insulin to lower blood glucose in patients whose hyperglycemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic agent.
Glyciphage Pg 1 Mg/500 Mg/15 Mg Tablet Sr is a drug that is used on treating patients suffering from type 2 Diabetes, who can’t control blood sugar levels through diet and exercise alone. Hence this drug is used to enhance the positive effects of diet and exercise with respect to blood sugar.
It is also used in combination with other antidiabetic medicines. It is a type of sulfonylurea antidiabetic medicine, that helps the pancreas in releasing insulin thus helping reduce the blood sugar level. It belongs to a class of drugs known as sulfonylureas.
Glyciphage Pg 1 Mg/500 Mg/15 Mg Tablet Sr is a type of sulfonylurea antidiabetic medicine which helps the pancreas in releasing insulin thus helping reduce the blood sugar level. It belongs to a class of drugs known as sulfonylureas. Glyciphage Pg 1 Mg/500 Mg/15 Mg Tablet Sr is available in oral tablet form.
Before starting a course of the medication, there are certain precautions that need to be taken. Firstly, any form of allergy must be mentioned to the consulting doctor. Also, if you have any history of kidney or liver diseases, it should be mentioned to the doctor.
Glyciphage Pg 1 Mg/500 Mg/15 Mg Tablet Sr makes the skin much more sensitive to the sun. Hence, if you are using this medication, use sunscreen to avoid skin problems. Limit the intake of alcohol during medication. Also, inform the doctor if you are currently using any prescribed drugs or diet supplement.
This drug shouldn’t be used by pregnant women. If you had a surgery recently, it is advisable not to take this medicine. The starting dose for Glyciphage Pg 1 Mg/500 Mg/15 Mg Tablet Sr is a 1mg tablet once every day. Glyciphage Pg 1 Mg/500 Mg/15 Mg Tablet Sr should be stored at a temperature between 20 to 25 degree Celcius. It should be kept away from heat, moisture and direct sunlight. Keep the drug away from the reach of the children and pets.
Symptoms of overdose include low blood sugar, tingling of lips and tongue, nausea, yawning, confusion, agitation, tachycardia, sweating, convulsions, stupor, and coma.
Intoxications with sulfonylureas can cause hypoglycemia and are best managed with glucose administration (oral for milder hypoglycemia or by injection in more severe forms). Patients should be monitored for a minimum of 24-48 hours after ingestion.
Glyciphage Pg 1 Mg/500 Mg/15 Mg Tablet Sr is used to control diabetes; it is not a cure. Other components of treatment plan are important: follow prescribed diet, medication, and exercise regimen. Take exactly as directed; 30 minutes before meal(s) at the same time each day.
Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Diabetologist before using this medicine.
Primary use of this medicine are as follows:
Type 2 Diabetes
Glyciphage 250 Tablet
Glyciphage 500mg Tablet
Glyciphage 850 Tablet
Glyciphage SR 1gmTablet
Glyciphage SR 500mg Tablet
Glyciphage SR 850mg Tablet
Glyciphage-G 1 Forte Tablet
Glyciphage-G 2 Forte Tablet
Glyciphage-G 1 Tablet
Glyciphage-G 2 Tablet
Glyciphage-PG 1 Tablet
Glyciphage-PG 2 Tablet
The side effects commonly occurred after the ingestion of this medicine:
Bone Marrow Suppression
Are there any missed dose instructions?
The missed dose can be taken as soon as you remember. If it is time for the next dosage then the missed dose can be skipped.
Are there any overdose instructions?
It is recommended to discontinue the medication and contact your doctor immediately if an overdose is suspected.
Glyciphage Pg 1 Mg/500 Mg/15 Mg Tablet Sr stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites.